902147-82-4

Upstream product

• 108-94-1 cyclohexanone 
• 50820-65-0 indole-6-carboxylic acid methyl ester 
• 1670-82-2 Indole-6-carboxylic acid 
• 494799-16-5 3-(cyclohex-1-en-1-yl)-1H-indole-6-carboxylic acid 
• 494799-17-6 3-cyclohexyl-1-methyl-1H-indole-6-carboxylic acid 
• 494799-18-7 methyl 3-cyclohexyl-1H-indole-6-carboxylate 
• 494799-19-8 methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate 
• 139962-95-1 2-formyl-4-methoxyphenylboronic acid 

Downstream Products

• 877291-15-1 13-cyclohexyl-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, dimethyl ester 
• 877291-09-3 13-cyclohexyl-3-(methyloxy)-10-((methyloxy)carbonyl)-7H-indolo[2,1-a][2]benzazepine-6-carboxylic acid 

Relevant academic research and scientific papers

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Indolobenzazepine HCV NS5B inhibitors

The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.